We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





Molecular Test Detects Three Arboviruses in Plasma Samples

By LabMedica International staff writers
Posted on 04 Aug 2016
Print article
Image: A digitally colorized transmission electron micrograph (TEM) of Zika virus. Viral particles are 40 nm in diameter with an outer envelope and dense inner core (Photo courtesy of Cynthia Goldsmith / CDC).
Image: A digitally colorized transmission electron micrograph (TEM) of Zika virus. Viral particles are 40 nm in diameter with an outer envelope and dense inner core (Photo courtesy of Cynthia Goldsmith / CDC).
Currently, multiple arboviruses are circulating in Brazil: Zika, chikungunya and dengue and they have similar clinical pictures, which can lead to misdiagnosis based on clinical grounds alone.

Detection tests for viral ribonucleic acid (RNA) such as the quantitative reverse transcription polymerase chain reaction (RT-qPCR) can reliably and specifically distinguish the three viruses and the specific diagnosis can be important in anticipating, preventing, and managing complications.

Scientists at the Laboratório Sabin (Brasília, Brazil) and their colleagues collected 90 plasma samples from the routine arbovirus laboratory, 20 positive for Zika (RT-qPCR), six positive for chikungunya (RT-qPCR), 18 positive for dengue nonstructural protein 1 antigen test (NS-1) and 46 negative for all three viruses. Nucleic acids were extracted from 1mL of sample by using an automated DNA extractor. An in-vitro transcribed random RNA sequence, which is not found in the nature, was spiked into plasmas during the nucleic acids extraction to function as a process control. Primers/probes for chikungunya were specifically designed for this study.

Zika, chikungunya and dengue viruses were assessed simultaneously by RT-qPCR, but in independent reaction wells. The control RNA was co-amplified in all instances. The viral loads of specific samples were quantified against a serial dilution of synthetic single-stranded DNA (ssDNA) and the limits of detection of each assay were determined by probit regression analysis. To investigate the precision of the assays, three samples at ~72, ~7.2 and ~0.72 copies/mL of each viruses were evaluated by using the Clinical and Laboratory Standards Institute (CLSI) EP12-A2 method during five days in quadruplicate by two operators.

The investigators reported that the limits of detection were 26 copies/mL for Zika, 23.5 copies/mL, for chikungunya and 25.6 copies/mL for dengue. The ~72, ~7.2 and ~0.72 copies/mL samples yielded 18/20 (90%), 2/20 (10%) and 1/20 (5%) positive results for Zika, 18/20 (90%), 4/20 (20%) and 0/20 (0%) positive results for chikungunya and 20/20 (100%), 16/20 (80%) and 0/20 (0%) positive results for dengue, respectively. The total, positive and negative agreements between compared methods were 95.5%, 90% and 97.5 for Zika, 100% for all methods for chikungunya and 95.6%, 100% and 94.5%, for dengue, respectively. No cross-reaction was observed.

The authors concluded that the RT-PCR method for simultaneous detection of Zika, chikungunya and dengue viruses is highly sensitive, all assays showed limit of detection below 50 copies/mL. Moreover, cut-off regions were characterized and acceptable precisions were observed for positive (~72 copies/mL and above) and negative (~0.72 copies/mL and below) results. Finally, the agreements with the comparative methods were very good, above 90% of concordance in all instances. The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.

Related Links:
Laboratório Sabin
American Association of Clinical Chemistry
New
Platinum Supplier
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Silver Supplier
Helicobacter Pylori Test
AB HP UREASE TEST
New
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus
New
Urine Analyzer
R-600S

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.